Loading clinical trials...
Loading clinical trials...
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer
Conditions
Interventions
Myelo001
Placebo
Locations
23
Germany
Site 20
Aachen, Germany
Site 16
Aurich, Germany
Site 21
Dresden, Germany
Site 26
Dresden, Germany
Site 05
Erlangen, Germany
Site 09
Esslingen am Neckar, Germany
Start Date
March 1, 2016
Primary Completion Date
November 1, 2017
Completion Date
November 1, 2017
Last Updated
November 24, 2017
NCT04541381
NCT05468034
NCT03137095
NCT04852887
NCT07547774
NCT07040891
Lead Sponsor
Myelo Therapeutics GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions